Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

26 August 2020 – MPA Webinar Series

Event #1 – Wed 26th August from 7pm to 830pm Topics: Dermatology and Melanoma Surgery Please register via the Eventbrite link: https://www.eventbrite.com.au/e/dermatology-and-melanoma-surgery-a-discussion-with-our-specialists-registration-116189932215?aff=ebdssbeac >> DOWNLOAD PDF for full details

Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Cancer in the News

Feature Articles

Spartalizumab combo with Tafinlar + Mekinist fails in Phase III advanced melanoma study

The Phase III COMBI-i study evaluating the immunotherapy spartalizumab (PDR001), in combination with…

Posted in Melanoma News, Health Professionals, Clinical Trials

Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

TMB is not just for melanoma, says Hamid. By examining TMB, investigators have done a significant job in helping to understand which patients will respond best to immunotherapy across a multitude of tumor types.

Posted in Melanoma News, Health Professionals, Video Reports

Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

Spartalizumab in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet the primary end point of investigator-assessed progression-free survival (PFS) in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma, according to an update on the phase 3 COMBI-i trial (NCT02967692).1

Posted in Melanoma News, Health Professionals, Clinical Trials

Mutational heterogeneity may be common in melanoma

Mutational heterogeneity was observed in almost 20% of melanoma tumors, according to a study.

Posted in Melanoma News, Health Professionals, Of Interest

Older Entries »